Evidence Building Program Policy
Read the Evidence Building Program policy for information on the program’s objectives, principles and inclusion criteria.
View Evidence Building Program Policy
Summary and Response to Stakeholder Consultation
This document summarizes the consultations that were held with clinicians, researchers, pharmacists, industry, associations, members of the public and academia during the development of the Evidence Building Program policy.
View Summary and Response to Stakeholder Consultation, 2011
Cancer Drug Funding and Administration in Ontario
Find an overview of the drug evaluation process in Ontario and the steps required before a cancer drug becomes a publicly-funded benefit in Ontario.
View Backgrounder: Cancer Drug Funding and Administration in Ontario
Program Status: EBP Trastuzumab (Herceptin) Update
The Ontario Ministry of Health has approved continued trastuzumab funding through the NDFP for the adjuvant treatment of HER2-positive breast cancer patients with node negative tumours less than or equal to 1cm in size.
Effective February 1, 2022, all new patients with this indication are eligible for funding of a trastuzumab biosimilar only, consistent with other NDFP trastuzumab policies.
View Program Status: EBP Trastuzumab (Herceptin) Update, February 2022